Potential cross-talk between (pro)renin receptors and Wnt/frizzled receptors in cardiovascular and renal disorders

Hypertension Research

Volumn 34, Issue 11, 2011, Pages 1161-1170

  Balakumar, Pitchai ^a   Jagadeesh, Gowraganahalli ^b  

^a Institute of Pharmacy   (India)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

(pro)renin receptor; frizzled receptor; renin angiotensin system; v H + ATPase; Wnt

Indexed keywords

BETA CATENIN; CALCIUM CHANNEL; FRIZZLED PROTEIN; GUANOSINE TRIPHOSPHATASE; PRORENIN RECEPTOR; TRANSIENT RECEPTOR POTENTIAL CHANNEL C;

CARDIOVASCULAR DISEASE; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; MOLECULAR INTERACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; CARDIOVASCULAR DISEASES; CELL SURVIVAL; DISEASE MODELS, ANIMAL; FRIZZLED RECEPTORS; HUMANS; KIDNEY DISEASES; RECEPTOR CROSS-TALK; RECEPTORS, CELL SURFACE; RECEPTORS, WNT; SIGNAL TRANSDUCTION;

EID: 80655125059     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2011.113     Document Type: Review

References (141)

1. Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis 2008; 4: 68-75. (Pubitemid 351881302)
2. Chien AJ, Conrad WH, Moon RT. A Wnt survival guide: from flies to human disease. J Invest Dermatol 2009; 129: 1614-1627.
3. Van de Schans VA, Smits JF, Blankesteijn WM. The Wnt/frizzled pathway in cardiovascular development and disease: friend or foe? Eur J Pharmacol 2008; 585: 338-345.
4. Gessert S, Kühl M. The multiple phases and faces of Wnt signaling during cardiac differentiation and development. Circ Res 2010; 107: 186-199.
5. Dejana E. The role of Wnt signaling in physiological and pathological angiogenesis. Circ Res 2010; 107: 943-952.
6. Schmidt-Ott KM, Barasch J. WNT/beta-catenin signaling in nephron progenitors and their epithelial progeny. Kidney Int 2008; 74: 1004-1008.
7. Van Es JH, Barker N, Clevers H. You Wnt some, you lose some: oncogenes in the Wnt signaling pathway. Curr Opin Genet Dev 2003; 13: 28-33. (Pubitemid 36143924)
8. MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell 2009; 17: 9-26.
9. Blankesteijn WM, Van de Schans VA, ter Horst P, Smits JF. The Wnt/frizzled/GSK-3 beta pathway: a novel therapeutic target for cardiac hypertrophy. Trends Pharmacol Sci 2008; 29: 175-180.
10. Balakumar P, Jagadeesh G. Multifarious molecular signaling cascades of cardiac hypertrophy: can the muddy waters be cleared? Pharmacol Res 2010; 62: 365-383.
11. Schulte G, Bryja V. The frizzled family of unconventional G-protein-coupled receptors. Trends Pharmacol Sci 2007; 28: 518-525. (Pubitemid 47488504)
12. Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 2006; 281: 22429-22433.
13. Kikuchi A, Yamamoto H, Kishida S. Multiplicity of the interactions of Wnt proteins and their receptors. Cell Signal 2007; 19: 659-671. (Pubitemid 46275377)
14. Kestler HA, Kuhl M. From individual Wnt pathways towards a Wnt signalling network. Philos Trans R Soc Lond B Biol Sci 2008; 363: 1333-1347. (Pubitemid 351311843)
15. Habas R, Dawid IB, Xi He. Coactivation of Rac and Rho by Wnt/Frizzled signaling is required for vertebrate gastrulation. Genes Dev 2003; 17: 295-309. (Pubitemid 36105900)
16. Povelones M, Howes R, Fish M, Nusse R. Genetic evidence that Drosophila frizzled controls planar cell polarity and Armadillo signaling by a common mechanism. Genetics 2005; 171: 1643-1654.
17. Slusarski DC, Corces VG, Moon RT. Interaction of Wnt and a Frizzled homologue triggers G-protein-linked phosphatidylinositol signalling. Nature 1997; 390: 410-413. (Pubitemid 28027323)
18. Malbon CC. Beta-catenin, cancer, and G proteins: not just for frizzleds anymore. Sci STKE 2005; 2005: pe35.
19. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007; 7: 79-94. (Pubitemid 46164746)
20. Tu X, Joeng KS, Nakayama KI, Nakayama K, Rajagopal J, Carroll TJ, McMahon AP, Long F. Noncanonical Wnt signaling through G protein-linked PKCd activation promotes bone formation. Dev Cell 2007; 12: 113-127. (Pubitemid 46002598)
21. Jernigan KK, Cselenyi CS, Thorne CA, Hanson AJ, Tahinci E, Hajicek N, Oldham WM, Lee LA, Hamm HE, Hepler JR, Kozasa T, Linder ME, Lee E. G beta gamma activates GSK3 to promote LRP6-mediated beta-catenin transcriptional activity. Sci Signal 2010; 3: ra37.
22. Wharton Jr KA. Runnin' with the Dvl: proteins that associate with Dsh/Dvl and their significance to Wnt signal transduction. Dev Biol 2003; 253: 1-17. (Pubitemid 36068000)
23. Angers S, Moon RT. Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol 2009; 10: 468-477.
24. Zoetis T, Hurtt ME. Species comparison of anatomical and functional renal development. Birth Defects Res B Dev Reprod Toxicol 2003; 68: 111-120. (Pubitemid 38222008)
25. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer J-D. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417-1427. (Pubitemid 34596167)
26. Balakumar P, Jagadeesh G. Cardiovascular and renal pathological implications of prorenin, renin and the prorenin receptor: Promising young players from the old renin angiotensin aldosterone system. J Cardiovasc Pharmacol 2010; 56: 570-579.
27. Nguyen G, Muller DN. The biology of the prorenin receptor. J Am Soc Nephrol 2010; 21: 18-23.
28. Cruciat CM, Ohkawara B, Acebron SP, Karaulanov E, Reinhard C, Ingelfinger D, Boutros M, Niehrs C. Requirement of prorenin receptor and vacuolar H+-ATPasemediated acidification for Wnt signaling. Science 2010; 327: 459-463.
29. Buechling T, Bartscherer K, Ohkawara B, Chaudhary V, Spirohn K, Niehrs C, Boutros M. Wnt/Frizzled signaling requires dPRR, the Drosophila homolog of the prorenin receptor. Curr Biol 2010; 20: 1263-1268.
30. Hermle T, Saltukoglu D, Grünewald J, Walz G, Simons M. Regulation of Frizzleddependent planar polarity signaling by a V-ATPase subunit. Curr Biol 2010; 20: 1269-1276.
31. Nguyen G. Renin and prorenin receptor in hypertension: what's new? Curr Hypertens Rep 2011; 13: 79-85.
32. Boutros M, Mlodzik M. Dishevelled: at the crossroads of divergent intracellular signaling pathways. Mech Dev 1999; 83: 27-37. (Pubitemid 29302079)
33. Penton A, Wodarz A, Nusse R. A mutational analysis of dishevelled in Drosophila defines novel domains in the dishevelled protein as well as novel suppressing alleles of axin. Genetics 2002; 161: 747-762. (Pubitemid 34705414)
34. Yost C, Torres M, Miller JR, Huang E, Kimelman D, Moon RT. The axis-inducing activity, stability, and subcellular distribution of beta-catenin is regulated in Xenopus embryos by glycogen synthase kinase 3. Genes Dev 1996; 10: 1443-1454. (Pubitemid 26260702)
35. He X, Semenov M, Tamai K, Zeng X. LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way. Development 2004; 131: 1663-1677. (Pubitemid 38559836)
36. Zeng X, Huang H, Tamai K, Zhang X, Harada Y, Yokota C, Almeida K, Wang J, Doble B, Woodgett J, Wynshaw-Boris A, Hsieh JC, He X. Initiation of Wnt signaling: control of Wnt coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions. Development 2008; 135: 367-375. (Pubitemid 351228428)
37. Piao S, Lee SH, Kim H, Yum S, Stamos JL, Xu Y, Lee SJ, Lee J, Oh S, Han JK, Park BJ, Weis WI, Ha NC. Direct inhibition of GSK3beta by the phosphorylated cytoplasmic domain of LRP6 in Wnt/beta-catenin signaling. PLoS One 2008; 3: e4046.
38. Ille F, Sommer L. Wnt signaling: multiple functions in neural development. Cell Mol Life Sci 2005; 62: 1100-1108. (Pubitemid 40868528)
39. Nusse R. WNT targets: repression and activation. Trends Genet 1999; 15: 1-3. (Pubitemid 29207333)
40. Arce L, Yokoyama NN, Waterman ML. Diversity of LEF/TCF action in development and disease. Oncogene 2006; 25: 7492-7504. (Pubitemid 44885748)
41. Rao TP, Kü hl M. An updated overview on Wnt signaling pathways: a prelude for more. Circ Res 2010; 106: 1798-1806.
42. Wilkins BJ, De Windt LJ, Bueno OF, Braz JC, Glascock BJ, Kimball TF, Molkentin JD. Targeted disruption of NFATc3, but not NFATc4, reveals an intrinsic defect in calcineurin mediated cardiac hypertrophic growth. Mol Cell Biol 2002; 22: 7603-7613.
43. Kerkela R, Kockeritz L, Macaulay K, Zhou J, Doble BW, Beahm C, Greytak S, Woulfe K, Trivedi CM, Woodgett JR, Epstein JA, Force T, Huggins GS. Deletion of GSK-3beta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J Clin Invest 2008; 118: 3609-3618.
44. Fujino H, West KA, Regan JW. Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. J Biol Chem 2002; 277: 2614-2619. (Pubitemid 34953286)
45. Yang M, Zhong WW, Srivastava N, Slavin A, Yang J, Hoey T, An S. G protein-coupled lysophosphatidic acid receptors stimulate proliferation of colon cancer cells through the b-catenin pathway. Proc Natl Acad Sci USA 2005; 102: 6027-6032. (Pubitemid 40594249)
46. Gardner S, Maudsley S, Millar RP, Pawson AJ. Nuclear stabilization of beta-catenin and inactivation of glycogen synthase kinase-3beta by gonadotropin-releasing hormone: targeting Wnt signaling in the pituitary gonadotrope. Mol Endocrinol 2007; 21: 3028-3038. (Pubitemid 350223512)
47. Wan M, Yang C, Li J, Wu X, Yuan H, Ma H, He X, Nie S, Chang C, Cao X. Parathyroid hormone signaling through low-density lipoprotein-related protein 6. Genes Dev 2008; 22: 2968-2979.
48. Rossol-Allison J, Stemmle LN, Swenson-Fields KI, Kelly P, Fields PE, McCall SJ, Casey PJ, Fields TA. Rho GTPase activity modulates Wnt3a/beta-catenin signaling. Cell Signal 2009; 21: 1559-1568.
49. Semenov MV, Tamai K, Brott BK, Kuhl M, Sokol S, He X. Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. Curr Biol 2001; 11: 951-961. (Pubitemid 32589186)
50. Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene 2006; 25: 7469-7481. (Pubitemid 44885746)
51. Hurlstone AF, Haramis AP, Wienholds E, Begthel H, Korving J, Van Eeden F, Cuppen E, Zivkovic D, Plasterk RH, Clevers H. The Wnt/beta-catenin pathway regulates cardiac valve formation. Nature 2003; 425: 633-637. (Pubitemid 37280148)
52. Waalen J. Current and emerging therapies for the treatment of osteoporosis. J Expt Pharmacol 2010; 2: 121-134.
53. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003; 116: 2627-2634. (Pubitemid 36857216)
54. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest 2006; 116: 1202-1209.
55. Varelas X, Miller BW, Sopko R, Song S, Gregorieff A, Fellouse FA, Sakuma R, Pawson T, Hunziker W, McNeill H, Wrana JL, Attisano L. The Hippo pathway regulates Wnt/beta-catenin signaling. Dev Cell 2010; 18: 579-591.
56. Pandur P, Lasche M, Eisenberg LM, Kuhl M. Wnt-11 activation of a non-canonical Wnt signalling pathway is required for cardiogenesis. Nature 2002; 418: 636-641.
57. Canapero L, Huang YL, Staudt N, Masasumi T, Ahrendt R, Kazanskaya O, Niehrs C, Houart C. Dickkopf-1 regulates gastrulation movements by coordinated modulation of Wnt/beta-catenin and Wnt/PCP activities, through interaction with the Dally-like homolog Knypek. Genes Dev 2007; 21: 465-480.
58. Maye P, Zheng J, Li L, Wu D. Multiple mechanisms for Wnt11-mediated repression of the canonical Wnt signaling pathway. J Biol Chem 2004; 279: 24659-24665. (Pubitemid 38725333)
59. Veeman MT, Axelrod JD, Moon RT. A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling. Dev Cell 2003; 5: 367-377. (Pubitemid 37107667)
60. Wong HC, Bourdelas A, Krauss A, Lee HJ, Shao Y, Wu D, Mlodzik M, Shi DL, Zheng J. Direct binding of the PDZ domain of Dishevelled to a conserved internal sequence in the C-terminal region of Frizzled. Mol Cell 2003; 12: 1251-1260. (Pubitemid 37487932)
61. Simons M, Gault WJ, Gotthardt D, Rohatgi R, Klein TJ, Shao Y, Lee HJ, Wu AL, Fang Y, Satlin LM, Dow JT, Chen J, Zheng J, Boutros M, Mlodzik M. Electrochemical cues regulate assembly of the Frizzled/Dishevelled complex at the plasma membrane during planar epithelial polarization. Nat Cell Biol 2009; 11: 286-294.
62. Wallingford JB, Habas R. The developmental biology of Dishevelled: an enigmatic protein governing cell fate and cell polarity. Development 2005; 132: 4421-4436. (Pubitemid 41632222)
63. Habas R, Kato Y, He X. Wnt/Frizzled activation of Rho regulates vertebrate gastrulation and requires a novel Formin homology protein Daam1. Cell 2001; 107: 843-854. (Pubitemid 34084976)
64. Tanegashima K, Zhao H, Dawid IB. WGEF activates Rho in the Wnt-PCP pathway and controls convergent extension in Xenopus gastrulation. EMBO J 2008; 27: 606-617. (Pubitemid 351273131)
65. Liu W, Sato A, Khadka D, Bharti R, Diaz H, Runnels LW, Habas R. Mechanism of activation of the Formin protein Daam1. Proc Natl Acad Sci USA 2008; 105: 210-215.
66. Li L, Yuan H, Xie W, Mao J, Caruso AM, McMahon A, Sussman DJ, Wu D. Dishevelled proteins lead to two signaling pathways. Regulation of LEF-1 and c-Jun N-terminal kinase in mammalian cells. J Biol Chem 1999; 274: 129-134. (Pubitemid 29035039)
67. Rosso SB, Sussman D, Wynshaw-Boris A, Salinas PC. Wnt signaling through dishevelled, Rac and JNK regulates dendritic development. Nat Neurosci 2005; 8: 34-42. (Pubitemid 41236729)
68. Kohn AD, Moon RT. Wnt and calcium signaling: beta-catenin-independent pathways. Cell Calcium 2005; 38: 439-446. (Pubitemid 41283282)
69. Slusarski DC, Pelegri F. Calcium signaling in vertebrate embryonic patterning and morphogenesis. Dev Biol 2007; 307: 1-13. (Pubitemid 46890853)
70. Kuhl M, Sheldahl LC, Malbon CC, Moon RT. Ca(2+)/calmodulin-dependent protein kinase II is stimulated by Wnt and frizzled homologs and promotes ventral cell fates in Xenopus. J Biol Chem 2000; 275: 12701-12711. (Pubitemid 30241421)
71. Sheldahl LC, Slusarski DC, Pandur P, Miller JR, Kuhl M, Moon RT. Dishevelled activates Ca2+ flux, PKC, and CamKII in vertebrate embryos. J Cell Biol 2003; 161: 769-777. (Pubitemid 36648760)
72. Nilsson LM, Sun ZW, Nilsson J, Nordström I, Chen YW, Molkentin JD, Wide-Swensson D, Hellstrand P, Lydrup ML, Gomez MF. Novel blocker of NFAT activation inhibits IL-6 production in human myometrial arteries and reduces vascular smooth muscle cell proliferation. Am J Physiol Cell Physiol 2007; 292: C1167-C1178. (Pubitemid 46440403)
73. Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006; 7: 589-600. (Pubitemid 44325350)
74. Kurayoshi M, Oue N, Yamamoto H, Kishida M, Inoue A, Asahara T, Yasui W, Kikuchi A. Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res 2006; 66: 10439-10448. (Pubitemid 44799765)
75. Cheng C, Yeh J, Fan T-P, Smith SK, Charnock-Jones DS. Wnt5a-mediated noncanonical Wnt signalling regulates human endothelial cell proliferation and migration. Biochem Biophys Res Commun 2008; 365: 285-290. (Pubitemid 350137286)
76. Kwon C, Cordes KR, Srivastava D. Wnt/beta-catenin signaling acts at multiple developmental stages to promote mammalian cardiogenesis. Cell Cycle 2008; 7: 3815-3818.
77. Van de Schans VA, Van den Borne SW, Strzelecka AE, Janssen BJ, Van der Velden JL, Langen RC, Wynshaw-Boris A, Smits JF, Blankesteijn WM. Interruption of Wnt signaling attenuates the onset of pressure overload-induced cardiac hypertrophy. Hypertension 2007; 49: 473-480.
78. Bergmann MW. WNT signaling in adult cardiac hypertrophy and remodeling: lessons learned from cardiac development. Circ Res 2010; 107: 1198-1208.
79. Baurand A, Zelarayan L, Betney R, Gehrke C, Dunger S, Noack C, Busjahn A, Huelsken J, Taketo MM, Birchmeier W, Dietz R, Bergmann MW. Betacatenin downregulation is required for adaptive cardiac remodeling. Circ Res 2007; 100: 1353-1362. (Pubitemid 46742926)
80. Zelarayán LC, Noack C, Sekkali B, Kmecova J, Gehrke C, Renger A, Zafiriou MP, Van der Nagel R, Dietz R, de Windt LJ, Balligand JL, Bergmann MW. Beta-catenin downregulation attenuates ischemic cardiac remodeling through enhanced resident precursor cell differentiation. Proc Natl Acad Sci USA 2008; 105: 19762-19767.
81. Huang Y, Ma YT, Yang YN, Liu F, Chen BD, Li XM. Association between wnt signal pathway and post-infarction cardiac remodeling/rupture in aged mice. Zhonghua Xin Xue Guan Bing Za Zhi. 2009; 37: 826-831.
82. Zhang CG, Jia ZQ, Li BH, Zhang H, Liu YN, Chen P, Ma KT, Zhou CY. Beta catenin/TCF/LEF1 can directly regulate phenylephrine-induced cell hypertrophy and Anf transcription in cardiomyocytes. Biochem Biophys Res Commun 2009; 390: 258-262.
83. Malekar P, Hagenmueller M, Anyanwu A, Buss S, Streit MR, Weiss CS, Wolf D, Riffel J, Bauer A, Katus HA, Hardt SE. Wnt signaling is critical for maladaptive cardiac hypertrophy and accelerates myocardial remodeling. Hypertension 2010; 55: 939-945.
84. Laragh J. Laragh's lessons in pathophysiology and clinical pearls for treating hypertension. Am J Hypertens 2001; 14: 186-194. (Pubitemid 32171573)
85. Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, Meiners S, Feldman DL, Webb RL, Garrelds IM, Jan Danser AH, Luft FC, Mü ller DN. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 2005; 46: 569-576. (Pubitemid 41376839)
86. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Suzuki F, Nakagawa T, Nishiyama A, Inagami T, Hayashi M. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 2006; 47: 894-900. (Pubitemid 44297561)
87. Nguyen, G. The prorenin receptor in health and disease. Ann Med 2010; 42: 3-18.
88. Ichihara A, Suzuki F, Nakagawa T, Kaneshiro Y, Takemitsu T, Sakoda M, Nabi AH, Nishiyama A, Sugaya T, Hayashi M, Inagami T. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor deficient mice. J Am Soc Nephrol 2006; 17: 1950-1961. (Pubitemid 44036179)
89. Nguyen G, Danser AH. The prorenin receptor: therapeutic consequences. Expert Opin Investig Drugs 2006; 15: 1131-1135.
90. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA, Border W. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006; 69: 105-113. (Pubitemid 43117745)
91. Saris JJ, Hoen PA, Garrelds IM, Dekkers DH, den Dunnen JT, Lamers JM, Jan Danser AH. Prorenin induces intracellular signaling in cardiomyocytes independently of angiotensin II. Hypertension 2006; 48: 564-571. (Pubitemid 44843857)
92. Funke-Kaiser H, Zollmann FS, Schefe JH, Unger T. Signal transduction of the prorenin receptor as a novel therapeutic target for preventing end organ damage. Hypertens Res 2010; 33: 98-104.
93. Sakoda M, Ichihara A, Kaneshiro Y, Takemitsu T, Nakazato Y, Nabi AH, Nakagawa T, Suzuki F, Inagami T, Itoh H. Prorenin receptor-mediated activation of mitogenactivated protein kinases in human vascular smooth muscle cells. Hypertens Res 2007; 30: 1139-1146.
94. He M, Zhang L, Shao Y, Wang X, Huang Y, Yao T, Lu L. Inhibition of renin/prorenin receptor attenuated mesangial cell proliferation and reduced associated fibrotic factor release. Eur J Pharmacol 2009; 606: 155-161.
95. Matavelli LC, Huang J, Siragy HM. Prorenin receptor contributes to diabetic nephropathy through enhancing renal inflammation. Clin Exp Pharmacol Physiol 2010; 37: 277-282.
96. Satofuka S, Ichihara A, Nagai N, Noda K, Ozawa Y, Fukamizu A, Tsubota K, Itoh H, Oike Y, Ishida S. Prorenin receptor-mediated signal transduction and tissue reninangiotensin system contribute to diabetes-induced retinal inflammation. Diabetes 2009; 58: 1625-1633.
97. Feldt S, Batenburg WW, Mazak I, Maschke U, Wellner M, Kvakan H, Dechend R, Fiebeler A, Burckle C, Contrepas A, Jan Danser AH, Bader M, Nguyen G, Luft FC, Muller DN. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008; 51: 682-688. (Pubitemid 351301521)
98. Schefe JH, Neumann C, Goebel M, Danser J, Kirsch S, Gust R, Kintscher U, Unger T, Funke-Kaiser H. Prorenin engages the prorenin receptor like renin and both ligand activities are unopposed by aliskiren. J Hypertens 2008; 26: 1787-1794.
99. Batenburg WW, Krop M, Garrelds IM, de Vries R, de Bruin RJA, Burcklé CA, Mü ller DN, Bader M, Nguyen G, Danser AH. Prorenin is the endogenous agonist of the prorenin receptor. Binding kinetics of renin and prorenin in rat vascular smooth muscle cells overexpressing the human prorenin receptor. J Hypertens 2007; 25: 2441-2453. (Pubitemid 350060383)
100. Susic D, Zhou X, Frohlich ED, Lippton H, Knight M. Cardiovascular effects of prorenin blockade in genetically hypertensive rats (SHR) on normal and high salt diet. Am J Physiol Heart Circ Physiol 2008; 295: H1117-H1121.
101. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, Koura Y, Nishiyama A, Okada H, Uddin MN, Nabi AH, Ishida Y, Inagami T, Saruta T. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the handle region for nonproteolytic activation of prorenin. J Clin Invest 2004; 114: 1128-1135. (Pubitemid 39578702)
102. Takahashi H, Ichihara A, Kaneshiro Y, Inomata K, Sakoda M, Takemitsu T, Nishiyama A, Itoh H. Regression of nephropathy developed in diabetes by prorenin receptor blockade. J Am Soc Nephrol 2007; 18: 2054-2061. (Pubitemid 47041071)
103. Derkx F, Schalekamp M. Human prorenin: pathophysiology and clinical implications. Clin Exp Hypertens A 1988; 10: 1213-1225. (Pubitemid 19051360)
104. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 2006; 24: 243-256. (Pubitemid 43348229)
105. Campbell DJ, Karam H, Ménard J, Bruneval P, Mullins JJ. Prorenin contributes to angiotensin peptide formation in transgenic rats with rat prorenin expression targeted to the liver. Hypertension 2009; 54: 1248-1253.
106. Peters B, Grisk O, Becher B, Wanka H, Kuttler B, Ludemann J, Lorenz G, Rettig R, Mullins JJ, Peters J. Dose-dependent titration of prorenin and blood pressure in Cyp1a1ren-2 transgenic rats: absence of prorenin-induced glomerulosclerosis. J Hypertens 2008; 26: 102-109. (Pubitemid 350301935)
107. Ichihara A, Sakoda M, Kurauchi-Mito A, Narita T, Kinouchi K, Murohashi-Bokuda K, Itoh H. Possible roles of human prorenin receptor suggested by recent clinical and experimental findings. Hypertens Res 2010; 33: 177-180.
108. Schefe JH, Menk M, Reinemund J, Effertz K, Hobbs RM, Pandolfi PP, Ruiz P, Unger T, Funke-Kaiser H. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res 2006; 99: 1355-1366. (Pubitemid 44949671)
109. Cousin C, Bracquart D, Contrepas A, Corvol P, Muller L, Nguyen G. Soluble form of the prorenin receptor generated by intracellular cleavage by furin is secreted in plasma. Hypertension 2009; 53: 1077-1082.
110. Zhou A, Carrell RW, Murphy MP, Wei Z, Yan Y, Stanley PL, Stein PE, Broughton Pipkin F, Read RJ. A redox switch in angiotensinogen modulates angiotensin release. Nature 2010; 468: 108-111.
111. Burcklé C, Bader M. Prorenin and its ancient receptor. Hypertension 2006; 48: 549-551. (Pubitemid 44843851)
112. Kinouchi K, Ichihara A, Sano M, Sun-Wada GH, Wada Y, Kurauchi-Mito A, Bokuda K, Narita T, Oshima Y, Sakoda M, Tamai Y, Sato H, Fukuda K, Itoh H. The prorenin receptor/ATP6AP2 is essential for vacuolar H+-ATPase assembly in murine cardiomyocytes. Circ Res 2010; 107: 30-34.
113. Advani A, Kelly DJ, Cox AJ, White KE, Advani SL, Thai K, Connelly KA, Yuen D, Trogadis J, Herzenberg AM, Kuliszewski MA, Leong-Poi H, Gilbert RE. The prorenin receptor: site-specific and functional linkage to the vacuolar H-ATPase in the kidney. Hypertension 2009; 54: 261-269.
114. Beyenbach KW, Wieczorek H. The V-type H+ ATPase: molecular structure and function, physiological roles and regulation. J Exp Biol 2006; 209: 577-589.
115. Amsterdam A, Nissen RM, Sun Z, Swindell EC, Farrington S, Hopkins N. Identification of 315 genes essential for early zebrafish development. Proc Natl Acad Sci USA 2004; 101: 12792-12797. (Pubitemid 39167537)
116. Contrepas A, Praizovic N, Duong Van Huyen JP, Lelievre-Pegorier M, Corvol P, Nguyen G. Expression of prorenin receptor in mouse embryonic and newborn kidney and proliferative effect of soluble (P)RR on mesangial cells [Abstract]. Hypertension 2007; 50: e145.
117. Ramser J, Abidi FE, Burckle CA, Lenski C, Toriello H, Wen G, Lubs HA, Engert S, Stevenson RE, Meindl A, Schwartz CE, Nguyen G. A unique exonic splice enhancer mutation in a family with X-linked mental retardation and epilepsy points to a novel role of the renin receptor. Hum Mol Genet 2005; 14: 1019-1027. (Pubitemid 40575877)
118. Sihn G, Rousselle A, Vilianovitch L, Burckle C, Bader M. Physiology of the prorenin receptor: Wnt of change? Kidney Int 2010; 78: 246-256.
119. Sorkin A, Von Zastrow M. Signal transduction and endocytosis: close encounters of many kinds. Nat Rev Mol Cell Biol 2002; 3: 600-614.
120. Ichimura T, Hatae T, Ishida T. Direct measurement of endosomal pH in living cells of the rat yolk sac epithelium by laser confocal microscopy. Eur J Cell Biol 1997; 74: 41-48. (Pubitemid 27416893)
121. George A, Leahy H, Zhou J, Morin PJ. The vacuolar-ATPase inhibitor bafilomycin and mutant VPS35 inhibit canonical Wnt signaling. Neurobiol Dis 2007; 26: 125-133. (Pubitemid 46436492)
122. Chen W, ten Berge D, Brown J, Ahn S, Hu LA, Miller WE, Caron MG, Barak LS, Nusse R, Lefkowitz RJ. Dishevelled 2 recruits beta-arrestin 2 to mediate Wnt5A-stimulated endocytosis of Frizzled 4. Science 2003; 301: 1391-1394. (Pubitemid 37075817)
123. Feldt S, Maschke U, Dechend R, Luft FC, Muller DN. The putative prorenin receptor blocker HRP fails to prevent prorenin signaling. J Am Soc Nephrol 2008; 19: 743-748.
124. Feldt S, Batenburg WW, Mazak I, Maschke U, Wellner M, Kvakan H, Dechend R, Fiebeler A, Burckle C, Contrepas A, Jan Danser AH, Bader M, Nguyen G, Luft FC, Muller DN. Prorenin and renin induced extracellular signal regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008; 51: 682-688. (Pubitemid 351301521)
125. Muller DN, Klanke B, Feldt S, Cordasic N, Hartner A, Schmieder RE, Luft FC, Hilgers KF. prorenin receptor peptide inhibitor 'handle-region' peptide does not affect hypertensive nephrosclerosis in Goldblatt rats. Hypertension 2008; 51: 676-681. (Pubitemid 351301520)
126. Wagner CA, Finberg KE, Breton S, Marshansky V, Brown D, Geibel JP. Renal vacuolar H+-ATPase. Physiol Rev 2004; 84: 1263-1314.
127. Prieto-Carrasquero MC, Botros FT, Pagan J, Kobori H, Seth DM, Casarini DE, Navar LG. Collecting duct renin is upregulated in both kidneys of 2-kidney, 1-clip goldblatt hypertensive rats. Hypertension 2008; 51: 1590-1596.
128. Rothenberger F, Velic A, Stehberger PA, Kovacikova J, Wagner CA. Angiotensin II stimulates vacuolar H+-ATPase activity in renal acid secretory intercalated cells from the outer medullary collecting duct. J Am Soc Nephrol 2007; 18: 2085-2093. (Pubitemid 47041074)
129. Pech V, Zheng W, Pham TD, Verlander JW, Wall SM. Angiotensin II activates H+-ATPase in type A intercalated cells. J Am Soc Nephrol 2008; 19: 84-91.
130. Kaneshiro Y, Ichihara A, Sakoda M, Takemitsu T, Nabi AH, Uddin MN, Nakagawa T, Nishiyama A, Suzuki F, Inagami T, Itoh H. Slowly progressive, angiotensin IIindependent glomerulosclerosis in human prorenin receptor-transgenic rats. J Am Soc Nephrol 2007; 18: 1789-1795. (Pubitemid 46870315)
131. Dai C, Stolz DB, Kiss LP, Monga SP, Holzman LB, Liu Y. Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol 2009; 20: 1997-2008.
132. Lancaster MA, Louie CM, Silhavy JL, Sintasath L, Decambre M, Nigam SK, Willert K, Gleeson JG. Impaired Wnt-beta-catenin signaling disrupts adult renal homeostasis and leads to cystic kidney ciliopathy. Nat Med 2009; 15: 1046-1054.
133. He W, Dai C, Li Y, Zeng G, Monga SP, Liu Y. Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol 2009; 20: 765-776.
134. Brade T, Männer J, Kühl M. The role of Wnt signalling in cardiac development and tissue remodelling in the mature heart. Cardiovasc Res 2006; 72: 198-209. (Pubitemid 44511910)
135. McMullen JR, Jennings GL. Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure. Clin Exp Pharmacol Physiol 2007; 34: 255-262.
136. Haq S, Choukroun G, Kang ZB, Ranu H, Matsui T, Rosenzweig A, Molkentin JD, Alessandrini A, Woodgett J, Hajjar R, Michael A, Force T. Glycogen synthase kinase-3beta is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol 2000; 151: 117-130.
137. Hilfiker-Kleiner D, Landmesser U, Drexler H. Molecular mechanisms in heart failure: focus on cardiac hypertrophy, inflammation, angiogenesis, and apoptosis. J Am Coll Cardiol 2006; 48: A56-A66. (Pubitemid 44648642)
138. Chen X, Shevtsov SP, Hsich E, Cui L, Haq S, Aronovitz M, Kerkelä R, Molkentin JD, Liao R, Salomon RN, Patten R, Force T. The beta-catenin/T-cell factor/lymphocyte enhancer factor signaling pathway is required for normal and stress-induced cardiac hypertrophy. Mol Cell Biol 2006; 26: 4462-4473. (Pubitemid 43877567)
139. Reudelhuber TL. Prorenin, renin, and their receptor: moving targets. Hypertension 2010; 55: 1071-1074.
140. Bader M. The second life of the prorenin receptor. J Renin Angiotensin Aldosterone Syst 2007; 8: 205-208.
141. Xu Q, Wang Y, Dabdoub A, Smallwood PM, Williams J, Woods C, Kelley MW, Jiang L, Tasman W, Zhang K, Nathans J. Vascular development in the retina and inner ear: control by Norrin and Frizzled-4, a high-affinity ligand-receptor pair. Cell 2004; 116: 883-895. (Pubitemid 38410732)